Diabetic Nephropathies Clinical Trial
Official title:
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have diabetic peripheral neuropathy (DPN). The study will enroll approximately 24 subjects. Subjects will be randomized to receive one of 3 treatments: PDA-002 (3 x 10^6 cells), PDA-002 (30 x 10^6 cells), or placebo (vehicle control) in a 1:1:1 randomization approach. Investigational product or placebo will be administered monthly (3 administrations total on Study Days 1, 29, and 57).
Subjects will undergo a Screening Period (up to 28 days in duration) to determine study eligibility and baseline levels of signs and symptoms of diabetic peripheral neuropathy (DPN) will be established. Subjects will then enter a Treatment Period (6 months in duration). During the Treatment Period, subjects will be evaluated on an ongoing basis (at 8 scheduled study visits). Subjects will receive intramuscular (IM) injections of investigational product (IP) on Study Days 1, 29, and 57 as fifteen 0.30 mL injections (below the knee and above the ankle) in one lower extremity in a blinded manner. After completing the Treatment Period, subjects will enter the Follow-up Period where they will continue to be evaluated at scheduled study visits over the subsequent months. An analysis of all study data will occur after the last subject has completed Visit 9 (Month 6) and after the last scheduled study visit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Terminated |
NCT01575379 -
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
|
Phase 4 | |
| Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
| Not yet recruiting |
NCT04084886 -
TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
|
||
| Active, not recruiting |
NCT04869761 -
Stem Cell Therapy for Chronic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT04570735 -
MRI Biomarkers in Diabetic Kidney Disease
|
||
| Completed |
NCT03165240 -
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
|
Phase 1 | |
| Completed |
NCT01968668 -
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
|
Phase 2 | |
| Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
| Terminated |
NCT02410005 -
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
|
Phase 2/Phase 3 | |
| Unknown status |
NCT01918488 -
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
|
N/A | |
| Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT03165227 -
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
|
Phase 1 | |
| Active, not recruiting |
NCT04531163 -
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03284996 -
Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.
|
N/A | |
| Completed |
NCT03334318 -
PERL Continuous Glucose Monitoring (CGM) Study
|
||
| Completed |
NCT04380584 -
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
|
||
| Recruiting |
NCT01320345 -
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
|
Phase 3 |